Literature DB >> 9753265

Esophageal irritation due to alendronate sodium tablets: possible mechanisms.

C P Peter1, L K Handt, S M Smith.   

Abstract

Animal studies were done using an in vivo dog model to examine the possible mechanism for the esophageal adverse events reported with alendronate sodium tablets. These studies showed that under low pH conditions alendronate sodium can cause esophageal irritation. No esophageal irritation occurred at pH 3.5 or higher where the drug exists primarily as the sodium salt. The animal studies also showed that alendronate sodium can exacerbate preexisting esophageal damage. Exposure of the esophageal mucosa for a prolonged period to alendronate sodium tablet can also cause mild esophageal irritation. These findings suggest that the esophageal irritation in patients taking Fosamax can be from prolonged contact with the tablet, reflux of acidic gastric contents with alendronate sodium, and exacerbation of preexisting esophageal damage. The findings also suggest that other bisphosphonates can cause esophageal injury under similar conditions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753265     DOI: 10.1023/a:1018894827961

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  8 in total

Review 1.  Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.

Authors:  J Y Reginster
Journal:  Bone       Date:  1992       Impact factor: 4.398

2.  Drug induced esophageal lesions studied in vitro.

Authors:  A Ryrfeldt; K Norbeck; S Reiland; P Moldéus
Journal:  Acta Physiol Scand Suppl       Date:  1990

3.  The ulcerogenic effect on the oesophagus of three beta-adrenoceptor antagonists, investigated in a new porcine oesophagus test model.

Authors:  S G Olovson; J A Björkman; L Ek; N Havu
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1983-11

4.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

5.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

6.  Pamidronate: an unrecognized problem in gastrointestinal tolerability.

Authors:  E G Lufkin; R Argueta; M D Whitaker; A L Cameron; V H Wong; K S Egan; W M O'Fallon; B L Riggs
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

7.  Appearance of a gastric ulcer during diphosphonate therapy in a woman with CRST syndrome.

Authors:  R L Saunders
Journal:  South Med J       Date:  1977-11       Impact factor: 0.954

Review 8.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

  8 in total
  25 in total

1.  Upper gastrointestinal ulceration with alendronate.

Authors:  J L Wallace
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

2.  A rare complication with a single dose of alendronate.

Authors:  Srinivasa Munigoti; Ricky Frazer; Alan Rees; Guy Blackshaw; Gareth Thomas; Aled Roberts
Journal:  BMJ Case Rep       Date:  2010-09-20

3.  Protective effect of melatonin and omeprazole against alendronat-induced gastric damage.

Authors:  Goksel Sener; Figen Onuk Goren; Nefise B Ulusoy; Yasemin Ersoy; Serap Arbak; Gül Ayanoglu Dülger
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

Review 4.  Alendronate: an update of its use in osteoporosis.

Authors:  M Sharpe; S Noble; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Alendronate-induced esophagitis in an elderly woman.

Authors:  Victoria Gómez; Shu-Yuan Xiao
Journal:  Int J Clin Exp Pathol       Date:  2008-06-20

Review 6.  A drinkable formulation of alendronate: potential to increase compliance and decrease upper GI irritation.

Authors:  Maria Luisa Brandi; Dennis Black
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

7.  Bisphosphonates for the treatment of osteoporosis: insights for clinicians.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

8.  A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.

Authors:  Toru Yoshioka; Nobukazu Okimoto; Ken Okamoto; Akinori Sakai
Journal:  J Bone Miner Metab       Date:  2012-10-19       Impact factor: 2.626

Review 9.  Advances in osteoporosis therapy. 2003 update of practical guidelines.

Authors:  Aliya Khan
Journal:  Can Fam Physician       Date:  2003-04       Impact factor: 3.275

Review 10.  Progress in osteoporosis and fracture prevention: focus on postmenopausal women.

Authors:  Kenneth G Saag; Piet Geusens
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.